Need professional-grade analysis? Visit stockanalysis.com
$2.45B
N/A
317
N/A
Price Chart
Risk-Adjusted Performance
Wave Life Sciences Ltd (WVE) Price Performance
Wave Life Sciences Ltd (WVE) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $7.34, down 2.00% from the previous close.
Over the past year, WVE has traded between a low of $5.94 and a high of $21.31. The stock has gained 8.1% over this period. It is currently 65.6% below its 52-week high.
Wave Life Sciences Ltd has a market capitalization of $2.45B.
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Compare Wave Life Sciences Ltd
Side-by-side comparison against top Healthcare peers.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $113.31M
- EBITDA
- $-211,943,008
- Profit Margin
- -478.33%
- EPS (TTM)
- -0.48
- Book Value
- 2.76
Technical Indicators
- 52 Week High
- $21.73
- 52 Week Low
- $5.02
- 50 Day MA
- $13.78
- 200 Day MA
- $9.98
- Beta
- -1.66
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 57.37
- Price/Book
- 4.73
- Enterprise Value
- $2.48B